Marie‐Christine Alessi

Author

Also Known As

ALESSI, MC., ALESSI, Marie-Christine, Alessi, Marie Christine, Alessi, Marie-Christine, Alessi, Mc, C. Aldasoro, F. Riva, I. Juhan-Vague, Ire`ne Juhan-Vague and Marie-Christine Alessi, J Amiral

549

Publications

32.1K

Citations

H-Index

214

Concepts

All Affiliations

Inserm Hôpital de la Timone Aix-Marseille Université Institut de Neurobiologie de la Méditerranée Sorbonne Université

About

Marie‐Christine Alessi is an author at Inserm specializing in medicine, thrombosis, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	61	135	17.9K
2	Health Sciences	32	44	11.6K
3	Public Health	19	20	1.2K
4	Natural Sciences	4	4	223
5	Engineering	1	1	17

Marie‐Christine Alessi

219

Publications

26.2K

Citations

H-Index

Page 1

	Year	Citations
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance Patrice D. Cani, Jacques Amar, Miguel A. Iglesias, Diabetes Metabolic DisorderHost-microbe InteractionsImmunologyInflammatory ToneBacterial Lipopolysaccharide	2007	6.2K
Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease Marie‐Christine Alessi, Franck Peiretti, Pierre‐Emmanuel Morange, Diabetes	1997	600
Energy intake is associated with endotoxemia in apparently healthy men Jacques Amar, Rémy Burcelin, Jean Bernard Ruidavets, American Journal of Clinical Nutrition ObesityNutritionMetabolic SyndromeEnergy MetabolismEnergy Homeostasis	2008	569
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris I. Juhan‐Vague, Stephen Pyke, Marie‐Christine Alessi, Circulation	1996	550
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). Paul Declerck, M De Mol, Marie‐Christine Alessi, Journal of Biological Chemistry	1988	486
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects P Vague, I. Juhan‐Vague, Marie Françoise Aillaud, Metabolism ObesityMetabolic SyndromeMetabolic DisorderCardiovascular DiseaseObese Subjects	1986	448
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study Thomas Cuisset, Pierre Deharo, Jacques Quilici, European Heart Journal	2017	393
PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events I. Juhan‐Vague, Marie‐Christine Alessi Thrombosis and Haemostasis ObesityMetabolic SyndromeInsulin ResistanceInsulin SignalingBody Composition	1997	388
High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome T. Cuisset, Corinne Frère, Jacques Quilici, Journal of Thrombosis and Haemostasis Percutaneous Coronary InterventionThrombosisDual Antiplatelet TherapyCardiovascular DiseaseBlood Platelet	2005	367
Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis I. Juhan‐Vague, J Valadier, Marie‐Christine Alessi, Thrombosis and Haemostasis	1987	367

Page 1